PURPOSE: Everolimus has demonstrated its efficacy in metastatic renal cell carcinoma (mRCC). Preliminary studies have shown high variability of everolimus blood concentrations (EBC). In other settings, its activity was correlated with EBC. We therefore decided to monitor EBC in patients treated with mRCC to assess its influence on oncologic outcomes. PATIENTS AND METHODS: Our study analyzed first 3 months' trough EBC levels in 42 patients treated in 4 French oncologic centers between March 2010 and August 2013. Patients presented a histologically confirmed diagnosis of mRCC and have failed prior anti-angiogenic (AA) therapies. RESULTS: Median follow-up was 25.9 months. A total of 113 EBC were analyzed. The median trough concentration was 14.1 μg/L (range 2.6-91.5). Fourteen patients (67 %) versus 8 (38 %) patients with median EBC above or below 14.1 μg/L were free from progression at 6 months (p = 0.06). Median progression-free survival was 13.3 versus 3.9 months (HR 0.66 95 % CI 0.33-1.31; p = 0.23), and the median overall survival was 26.2 versus 9.9 months (HR 0.62 95 % CI 0.28-1.37; p = 0.24), for patients above or below the median value of trough concentrations, respectively. CONCLUSION: Impact of drug exposure for AA tyrosine kinase inhibitors activity has been demonstrated in mRCC setting. Interpatients EBC variability was confirmed in the present study, and the results suggest a relationship between initial EBC within the first 3 months and the drug activity. It underlines the need to prospectively include EBC monitoring in future clinical trials to determine the need of its implementation in routine use.
PURPOSE:Everolimus has demonstrated its efficacy in metastatic renal cell carcinoma (mRCC). Preliminary studies have shown high variability of everolimus blood concentrations (EBC). In other settings, its activity was correlated with EBC. We therefore decided to monitor EBC in patients treated with mRCC to assess its influence on oncologic outcomes. PATIENTS AND METHODS: Our study analyzed first 3 months' trough EBC levels in 42 patients treated in 4 French oncologic centers between March 2010 and August 2013. Patients presented a histologically confirmed diagnosis of mRCC and have failed prior anti-angiogenic (AA) therapies. RESULTS: Median follow-up was 25.9 months. A total of 113 EBC were analyzed. The median trough concentration was 14.1 μg/L (range 2.6-91.5). Fourteen patients (67 %) versus 8 (38 %) patients with median EBC above or below 14.1 μg/L were free from progression at 6 months (p = 0.06). Median progression-free survival was 13.3 versus 3.9 months (HR 0.66 95 % CI 0.33-1.31; p = 0.23), and the median overall survival was 26.2 versus 9.9 months (HR 0.62 95 % CI 0.28-1.37; p = 0.24), for patients above or below the median value of trough concentrations, respectively. CONCLUSION: Impact of drug exposure for AA tyrosine kinase inhibitors activity has been demonstrated in mRCC setting. Interpatients EBC variability was confirmed in the present study, and the results suggest a relationship between initial EBC within the first 3 months and the drug activity. It underlines the need to prospectively include EBC monitoring in future clinical trials to determine the need of its implementation in routine use.
Authors: Neeltje Steeghs; Alwin D R Huitema; Stefanie L Groenland; Remy B Verheijen; Markus Joerger; Ron H J Mathijssen; Alex Sparreboom; Jos H Beijnen; Jan H Beumer Journal: Clin Cancer Res Date: 2021-09-21 Impact factor: 12.531
Authors: Annelieke E C A B Willemsen; Lioe-Fee de Geus-Oei; Maaike de Boer; Jolien Tol; Yvonne Kamm; Paul C de Jong; Marianne A Jonker; Allert H Vos; Willem Grootjans; Johannes W B de Groot; Sasja F Mulder; Erik H J G Aarntzen; Winald R Gerritsen; Carla M L van Herpen; Nielka P van Erp Journal: Target Oncol Date: 2018-10 Impact factor: 4.493
Authors: D de Wit; T C Schneider; D J A R Moes; C F M Roozen; J den Hartigh; H Gelderblom; H J Guchelaar; J J van der Hoeven; T P Links; E Kapiteijn; N P van Erp Journal: Cancer Chemother Pharmacol Date: 2016-05-11 Impact factor: 3.333
Authors: Remy B Verheijen; Huixin Yu; Jan H M Schellens; Jos H Beijnen; Neeltje Steeghs; Alwin D R Huitema Journal: Clin Pharmacol Ther Date: 2017-09-07 Impact factor: 6.875
Authors: A E C A B Willemsen; L M Knapen; Y M de Beer; R J M Brüggemann; S Croes; C M L van Herpen; N P van Erp Journal: Eur J Clin Pharmacol Date: 2017-12-08 Impact factor: 2.953
Authors: Nielka P van Erp; Carla M van Herpen; Djoeke de Wit; Annelieke Willemsen; David M Burger; Alwin D R Huitema; Ellen Kapiteijn; Rob Ter Heine Journal: Clin Pharmacokinet Date: 2016-11 Impact factor: 6.447
Authors: Arindam P Ghosh; Christopher B Marshall; Tatjana Coric; Eun-Hee Shim; Richard Kirkman; Mary E Ballestas; Mitsuhiko Ikura; Mary-Ann Bjornsti; Sunil Sudarshan Journal: Oncotarget Date: 2015-07-20
Authors: Remy B Verheijen; Florence Atrafi; Jan H M Schellens; Jos H Beijnen; Alwin D R Huitema; Ron H J Mathijssen; Neeltje Steeghs Journal: Clin Pharmacokinet Date: 2018-05 Impact factor: 6.447